For research use only
| Cat No. | ABC-TC3973 |
| Product Type | Nervous Cells |
| Cell Type | DC Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human dendritic cells from blood activate T cells, express CD11c, CD80, HLA-DR, non-proliferative, used in cancer immunotherapy and infectious disease.
Human dendritic cells (DCs) are specialized antigen-presenting cells derived from peripheral blood of healthy human donors. They are key modulators in immune surveillance, tolerance, and inflammation, and are involved in various diseases including cancer, autoimmune disorders, and infectious diseases. They possess characteristic dendritic morphology with branched cytoplasmic projections that facilitate antigen capture and interaction with T cells. In culture, human DCs are non-proliferative and survive for up to 7 days as immature dendritic cells (iDCs) when treated with IL-4 and GM-CSF, and can further differentiate into mature dendritic cells with TNF-α and IL-1β. They express a characteristic surface marker profile including CD11c⁺, CD80⁺, CD86⁺, HLA-DR⁺. Human DCs are widely used in cancer immunotherapy, infectious disease models, and autoimmune disorder research due to their potent antigen-presenting capacity and immunomodulatory role.
| Product Code | Human Dendritic Cells, DCs, Human Antigen Presenting Cells, Myeloid Dendritic Cells |
| Species | Human |
| Cat.No | ABC-TC3973 |
| Product Category | Primary Cells |
| Size/Quantity | 1 vial |
| Cell Type | DC Cell |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Nervous Cells |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Human dendritic cells (DCs) can be used to simulate pathogen-host interactions (such as HIV, SARS-CoV-2) in infectious disease research and evaluate vaccine efficacy through antigen cross-presentation. In addition, in the study of autoimmune diseases, DCs help to elucidate the mechanism of immune tolerance destruction (such as rheumatoid arthritis) and are used to test tolerogenic DC-based therapies to inhibit abnormal immune activation.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).